Allergan Defends 3-Month Exclusivity Deal For Namenda

Law360, New York (March 17, 2017, 6:48 PM EDT) -- Pharmaceutical patent holders that sue generic-drug manufacturers for infringement and then shorten product exclusivity periods via settlements shouldn’t have to actually win those cases to maintain exclusivity, an Allergan unit told a New York federal judge Friday in a lawsuit over Alzheimer’s treatment Namenda.

Forest Laboratories LLC is seeking partial summary judgment on a claim brought by drug wholesalers regarding exclusivity for the pediatric use of Namenda, and both Forest and Merz GmbH, who are defendants in the lawsuit, are opposing the wholesalers’ motion for summary...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.